卵巢恶性肿瘤保留生育功能的中国专家共识(2022年版)
本文刊登于《中国实用妇科与产科杂志》2022,38(7):705-713
DOI:10.19538/j.fk2022070110
【引用本文】中国优生科学协会肿瘤生殖学分会,中国医师协会微无创医学专业委员会妇科肿瘤学组,中国医院协会妇产医院分会妇科肿瘤专业学组.卵巢恶性肿瘤保留生育功能的中国专家共识(2022年版)[J].中国实用妇科与产科杂志,2022,38(7):705-713.
作者:中国优生科学协会肿瘤生殖学分会 中国医师协会微无创医学专业委员会妇科肿瘤学组 中国医院协会妇产医院分会妇科肿瘤专业学组
基金项目:国家自然科学基金(81960464);广西医疗卫生适宜技术开发与推广应用项目(S2019103)
通讯作者:王玉东,上海交通大学医学院附属国际和平妇幼保健院,上海 200030,电子信箱:owangyudong@126.com;张师前,山东大学齐鲁医院,山东 济南 250012,电子信箱:r370112@126.com;范江涛,广西医科大学第一附属医院,广西 南宁 530021,电子信箱:jiangtao_fan1969@163.com
执笔专家:孙丹(广西医科大学第一附属医院);范江涛(广西医科大学第一附属医院),张师前(山东大学齐鲁医院);王建东(首都医科大学附属北京妇产医院);王玉东(上海交通大学医学院附属国际和平妇幼保健院)
参与共识讨论专家(排名不分先后):孙丹(广西医科大学第一附属医院);范江涛(广西医科大学第一附属医院);张师前(山东大学齐鲁医院);王建东(首都医科大学附属北京妇产医院);王玉东(上海交通大学医学院附属国际和平妇幼保健院);王继东(山东省妇幼保健院);许天敏(吉林大学第二医院);蔡红兵(武汉大学中南医院);贺红英(广西医科大学附属柳铁中心医院);李长忠(北京大学深圳医院);娄阁(哈尔滨医科大学附属肿瘤医院);陆琦(复旦大学附属金山医院);孙阳(福建省肿瘤医院);孙蓬明(福建省妇幼保健院);王平(四川大学华西二院);王武亮(郑州大学第二附属医院);邹冬玲(重庆大学附属肿瘤医院);王莉(河南省肿瘤医院);王延洲(陆军军医大学第一附属医院);吴强(江苏省肿瘤医院);于浩(山东第一医科大学附属肿瘤医院);董延磊(山东大学第二医院);杨英捷(贵州省肿瘤医院);张颐(中国医科大学附属第一医院);王颖梅(天津医科大学总医院);师伟(山东中医药大学附属医院);王刚(四川省妇幼保健院);王小元(山东第一医科大学第一附属医院);韦德英(山东第一医科大学附属省立医院);程晓东(浙江大学医学院附属妇产科医院);阳志军(广西医科大学附属肿瘤医院);任琛琛(郑州大学第三附属医院);沈杨(东南大学附属中大医院);谭文华(哈尔滨医科大学第二附属医院);孔为民(首都医科大学附属北京妇产医院);李斌(中国医学科学院肿瘤医院);张国楠(四川省肿瘤医院);马晓欣(中国医科大学附属盛京医院);林蓓(中国医科大学附属盛京医院);王沂峰(南方医科大学珠江医院);李俊东(中山大学肿瘤医院);刘淑娟(空军军医大学西京医院);熊光武(北京大学国际医院);洪莉(武汉大学人民医院);王丹波(辽宁省肿瘤医院);郭瑞霞(郑州大学第一附属医院);朱前勇(河南省人民医院);陆安伟(南方医科大学深圳医院);王静(湖南省肿瘤医院);王永军(北京大学第四临床医学院);王世军(首都医科大学北京宣武医院);魏代敏(山东大学附属生殖医院);黄守国(中南大学湘雅海口医院);符淳(中南大学湘雅第二医院);纪妹(郑州大学第一附属医院);蔡丽萍(南昌大学第一附属医院);王建六(北京大学人民医院);孟元光(解放军总医院妇产医学部);覃爱平(广西医科大学第一附属医院);刘畅(兰州大学第一医院);唐均英(重庆医科大学附属第一医院);周圣涛(四川大学华西第二医院)
1 背景
2 卵巢恶性肿瘤保留生育功能的手术治疗
2.1 早期上皮性卵巢癌
2.2 卵巢恶性生殖细胞肿瘤
2.3 早期卵巢性索间质肿瘤
3 FSS术后的辅助治疗
3.1 早期上皮性卵巢癌
3.2 卵巢恶性生殖细胞肿瘤
3.3 早期卵巢性索间质肿瘤
4 生育力评估及遗传咨询
4.1 生育力评估
4.2 遗传咨询
5 FSS后妊娠和随访相关问题
[1] Crafton SM,Cohn DE,Llamocca EN,et al.Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries[J].Cancer,2020 ,126(6):1217-1224.
[2] International Agency for Research on Cancer(IARC).Global cancer observatory[EB/OL].(2020-11-17).https://gco.iarc.fr.
[3] Torre LA,Trabert B,DeSantis CE,et al.Ovarian cancer statistics,2018[J].CA Cancer J Clin,2018,68(4):284-296.
[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18.
[5] Shah JS,Guerra R,Bodurka DC,et al.Factors influencing fertility-sparing treatment for gynecologic malignancies:a survey of Society of Gynecologic Oncology members[J].Gynecol Oncol,2017,147(3):497-502.
[6] WHO Classification of Tumours Editorial Board.Female genital tumours--WHO classification of tumours series,5th ed.Vol.4[M].Lyon(France):International Agency for Research on Cancer,2020.
[7] Mutch DG,Prat J.2014 FIGO staging for ovarian,fallopian tube and peritoneal cancer[J].Gynecol Oncol,2014,133(3):401-404.
[8] 马丁.卵巢癌研究进展与规范化治疗[J].中国实用妇科与产科杂志,2021,37(6):601-604.
[9] 邓黎,梁志清.微创手术在卵巢癌治疗中的应用与争议[J].中国实用妇科与产科杂志,2021,37(6):620-623. .
[10] National Comprehensive Cancer Network.NCCN guideline in ovarian cancer/fallopian tube cancer/primary peritoneal cancer(Version 1.2022)[EB/OL].(2022-03-02).https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
[11] 张师前,魏代敏.重视妇科恶性肿瘤内分泌功能保护及生殖管理[J].中国实用妇科与产科杂志,2019,35(6):612-613.
[12] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):490-500.
[13] 郭丽,王忱,张萍,等.高级别浆液性卵巢癌的分子遗传学研究进展[J].中国实用妇科与产科杂志,2021,37(9):982-984.
[14] Bowtell DD,Böhm S,Ahmed AA,et al.Rethinking ovarian cancer II:reducing mortality from high-grade serous ovarian cancer[J].Nat Rev Cancer,2015,15(11):668-679.
[15] Matulonis UA,Sood AK,Fallowfield L,et al. Ovarian cancer[J].Nat Rev Dis Primers,2016,2:16061.
[16] Fruscio R,Corso S,Ceppi L,et al.Conservative management of early-stage epithelial ovarian cancer:results of a large retrospective series[J].Ann Oncol,2013,24(1):138-144.
[17] 周灿权,黄孙兴.重视女性生育力的保护与保存[J].中国实用妇科与产科杂志,2022,38(6):577-579.
[18] Matsuo K,Machida H,Grubbs BH,et al.Trends of low-grade serous ovarian carcinoma in the United States[J].J Gynecol Oncol,2018,29(1):e15.
[19] Sieh W,Köbel M,Longacre TA,et al.Hormone-receptor expression and ovarian cancer survival:an ovarian tumor tissue analysis consortium study[J].Lancet Oncol,2013,14(9):853-862.
[20] Gershenson DM,Bodurka DC,Lu KH,et al.Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum:results of a large single-institution registry of a rare tumor[J].J Clin Oncol,2015,33(24):2675-2682.
[21] Jiang X,Yang J,Yu M,et al.Oncofertility in patients with stage I epithelial ovarian cancer:fertility-sparing surgery in young women of reproductive age[J].World J Surg Oncol,2017,15(1):154.
[22] Duska LR,Chang YC,Flynn CE,et al.Epithelial ovarian carcinoma in the reproductive age group[J].Cancer,1999,85(12):2623-2629.
[23] Kajiyama H,Shibata K,Suzuki S,et al.Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?[J].Gynecol Oncol,2008,111(3):523-526.
[24] De Nonneville A,Zemmour C,Frank S,et al.Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma:Analysis of the French national ESME-Unicancer database[J].Gynecol Oncol,2021,163(1):64-71.
[25] Köbel M,Kalloger SE,Huntsman DG,et al.Differences in tumor type in low-stage versus high-stage ovarian carcinomas[J].Int J Gynecol Pathol,2010,29(3):203-211.
[26] Kajiyama H,Mizuno M,Shibata K,et al.Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery:a multi-institutional study[J].Eur J Obstet Gynecol Reprod Biol,2014,175:97-102.
[27] Gouy S,Saidani M,Maulard A,et al.Results of fertility-sparing surgery for expansile and infiltrative mucinous ovarian cancers[J].Oncologist,2018,23(3):324-327.
[28] Shimada M,Kigawa J,Ohishi Y,et al.Clinicopathological characteristics of mucinous adenocarcinoma of the ovary[J].Gynecol Oncol,2009,113(3):331-334.
[29] 韩丽萍,刘丽雅.卵巢非上皮性恶性肿瘤生育力保护[J].中国实用妇科与产科杂志,2019,35(6):626-631.
[30] Morrison A,Nasioudis D.Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors:asystematic review of the literature[J].Gynecol Oncol,2020,158(2):476-483.
[31] Boran N,Tulunay G,Caliskan E,et al.Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas[J].Arch Gynecol Obstet,2005,271(2):104-108.
[32] Park JY,Kim DY,Suh DS,et al.Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors[J].Gynecol Oncol,2017,145(3):513-518.
[33] Ray-Coquard I,Brown J,Harter P,et al.Gynecologic Cancer InterGroup(GCIG) consensus review for ovarian sex cord stromal tumors[J].Int J Gynecol Cancer,2014,24(9 Suppl 3):S42-S47.
[34] Gouy S,Arfi A,Maulard A,et al.Results from a monocentric long-term analysis of 23 patients with ovarian Sertoli-Leydig cell tumors[J].Oncologist,2019,24(5):702-709.
[35] Schneider DT,Orbach D,Cecchetto G,et al.Ovarian Sertoli Leydig cell tumours in children and adolescents:an analysis of the European Cooperative Study Group on Pediatric Rare Tumors(EXPeRT)[J].Eur J Cancer,2015,51(4):543-550.
[36] 袁增,宋坤,孔北华.遗传性卵巢癌预防性附件切除术的相关问题与争议[J].中国实用妇科与产科杂志,2021,37(6):623-627.
[37] Griffiths MJ,Winship AL,Hutt KJ.Do cancer therapies damage the uterus and compromise fertility?[J].Hum Reprod Update,2020,26(2):161-173.
[38] Oktay K,Harvey BE,Partridge AH,et al.Fertility preservation in patients with cancer:ASCO clinical practice guideline update[J].J Clin Oncol,2018,36(19):1994-2001.
[39] Lambertini M,Peccatori FA,Demeestere I,et al.Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients:ESMO Clinical Practice Guidelines[J].Ann Oncol,2020,31(12):1664-1678.
[40] 中华医学会生殖医学分会.生育力保存中国专家共识[J].生殖医学杂志,2021,30(9):1129-1134.
[41] Wilson MK,Fong P,Mesnage S,et al.Stage I granulosa cell tumours:a management conundrum? Results of long-term follow-up[J].Gynecol Oncol,2015,138(2):285-291.
[42] Ma N,Chen G,Chen J,et al.Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin‑releasing hormone agonist[J].Oncol Rep,2020 ,44(5):1917-1928.
[43] Fornier MN,Modi S,Panageas KS,et al.Incidence of chemotherapy-induced,long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane[J].Cancer,2005,104(8):1575-1579.
[44] Tarumi W,Suzuki N,Takahashi N,et al.Ovarian toxicity of paclitaxel and effect on fertility in the rat[J].J Obstet Gynaecol Res,2009,35(3):414-420.
[45] Anderson RA,Themmen AP,Al-Qahtani A,et al.The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer[J].Hum Reprod,2006,21(10):2583-2592.
[46] Ntemou E,Vidal PD,Alexandri C,et al.Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene[J].Sci Rep,2022,12(1):1658.
[47] Nasioudis D,Mastroyannis SA,Albright BB,et al. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma:patterns of use and outcomes[J].Gynecol Oncol,2018,150(1):14-18.
[48] Weinberg LE,Lurain JR,Singh DK,et al.Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors[J].Gynecol Oncol,2011,121(2):285-289.
[49] Gadducci A,Lanfredini N,Tana R.Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours[J].Gynecol Endocrinol,2014,30(7):467-471.
[50] Gaffan J,Holden L,Newlands ES,et al.Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours-a retrospective long-term follow-up study[J].Br J Cancer,2003,89(10):1849-1854.
[51] Blommaert FA,Michael C,van Dijk-Knijnenburg HC,et al.The formation and persistence of carboplatin-DNA adducts in rats[J].Cancer Chemother Pharmacol,1996,38(3):273-280.
[52] Higdon RE,Marchetti F,Mailhes JB,et al.The effects of cisplatin on murine metaphase Ⅱ oocytes[J].Gynecol Oncol,1992,47(3):348-352.
[53] Patterson P,McDonald FE,Zebrack B,et al.Emerging issues among adolescent and young adult cancer survivors[J].Semin Oncol Nurs,2015,31(1):53-59.
[54] Hohmann C,Borgmann-Staudt A,Rendtorff R,et al.Patient counselling on the risk of infertility and its impact on childhood cancer survivors:results from a national survey[J].J Psychosoc Oncol,2011,29(3):274-285.
[55] Su HC,Haunschild C,Chung K,et al.Prechemotherapy antimullerian hormone,age,and body size predict timing of return of ovarian function in young breast cancer patients[J].Cancer,2014,120(23):3691-3698.
[56] Silva C,Caramelo O,Almeida-Santos T,et al.Factors associated with ovarian function recovery after chemotherapy for breast cancer:a systematic review and meta-analysis[J].Hum Reprod,2016,31(12):2737-2749.
[57] Barnabei A,Strigari L,Marchetti P,et al.Predicting ovarian activity in women affected by early breast cancer:a meta-analysis-based nomogram[J].Oncologist,2015,20(10):1111-1118.
[58] Jones MR,Kamara D,Karlan BY,et al.Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction[J].Gynecol Oncol,2017,147(3):705-713.
[59] Alsop K,Fereday S,Meldrum C,et al.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group[J].J Clin Oncol,2012,30(21):2654-2663.
[60] Heravi-Moussavi A,Anglesio MS,Cheng SW,et al.Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers[J].N Engl J Med,2012,366(3):234-242.
[61] Shah SP,Kobel M,Senz J,et al.Mutation of FOXL2 in granulosa-cell tumors of the ovary[J].N Engl J Med,2009,360(26):2719-2729.
[62] Van Nieuwenhuysen E,Lambrechts S,Lambrechts D,et al.Genetic changes in nonepithelial ovarian cancer[J].Expert Rev Anticancer Ther,2013,13(7):871-882.
[63] De Paolis E,Paragliola RM,Concolino P.Spectrum of DICER1 germline pathogenic variants in ovarian Sertoli-Leydig cell tumor[J].J Clin Med,2021,10(9):1845.
[64] Finch AP,Lubinski J,Moller P,et al.Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation[J].J Clin Oncol,2014,32:1547-1553.
[65] Daly MB,Pilarski R,Berry M,et al.NCCN Guidelines insights:genetic/familial high-risk assessment:breast and ovarian,version 2.2017[J].J Natl Compr Canc Netw,2017,15(1):9-20.
[66] Turan V,Lambertini M,Lee DY,et al.Association of germline BRCA pathogenic variants with diminished ovarian reserve:a meta-analysis of individual patient-level data[J].J Clin Oncol,2021,39(18):2016-2024.
[67] Lin W,Titus S,Moy F,et al.Ovarian aging in women with BRCA germline mutations[J].J Clin Endocrinol Metab,2017,102(10):3839-3847.
[68] Lambertini M,Goldrat O,Toss A,et al.Fertility and pregnancy issues in BRCA-mutated breast cancer patients[J].Cancer Treat Rev,2017,59:61-70.
[69] Turan V,Oktay K.BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging[J].Hum Reprod Update,2020,26(1):43-57.
[70] ESHRE Guideline Group on Female Fertility Preservation,Anderson RA,Amant F,et al.ESHRE guideline:female fertility preservation[J].Hum Reprod Open,2020,2020(4):hoaa052.
[71] Gatta G,van der Zwan JM,Casali PG,et al.Rare cancers are not so rare:the rare cancer burden in Europe[J].Eur J Cancer,2011,47(17):2493-2511.
[72] 薛凤霞,滕飞,魏丽坤.妇科恶性肿瘤保留生育功能生育结局[J].中国实用妇科与产科杂志,2019,35(6):646-651.
[73] Canlorbe G,Chabbert-Buffet N,Uzan C.Fertility-sparing surgery for ovarian cancer[J].J Clin Med,2021,10(18):4235.
[74] Johansen G,Dahm-Kähler P,Staf C,et al.Fertility-sparing surgery for treatment of non-epithelial ovarian cancer:oncological and reproductive outcomes in a prospective nationwide population-based cohort study[J].Gynecol Oncol,2019,155(2):287-293.
[75] Yang B,Yu Y,Chen J,et al.Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant-a Chinese retrospective cohort study among 148 cases[J].Front Med,2018,12(5):509-517.
[76] Zanetta G,Bonazzi C,Cantù M,et al.Survival and reproductive function after treatment of malignant germ cell ovarian tumors[J].J Clin Oncol,2001,19(4):1015-1020.
[77] de La Motte RT,Pautier P,Duvillard P,et al.Survival and reproductive function of 52 women treated with surgery and bleomycin,etoposide,cisplatin(BEP) chemotherapy for ovarian yolk sac tumor[J].Ann Oncol,2008,19(8):1435-1441.
[78] Zhang N,Chen R,Hua K,et al.A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors[J].J Ovarian Res,2017,10(1):52.
[79] Tangir J,Zelterman D,Ma W,et al.Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary[J].Obstet Gynecol,2003,101(2):251-257.
[80] Wang D,Cao D,Jia C,et al.Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors[J].Gynecol Oncol,2018,151(2):275-281.
[81] Wang D,Zhu S,Jia C,et al.Oncological and reproductive outcomes of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing surgery in patients with apparent early stage pure immature ovarian teratomas[J].Ann Surg Oncol,2021,28(11):6684-6693.
参考文献滑动预览